Dr Sujith Subesinghe on biologic prescribing decisions following serious infection in RA patients

Dr James Galloway talks to Dr Sujith Subesinghe, Kings College London, about his recent paper which looked at biologic prescribing decisions following serious infection in RA patients. Analyses of data from the British Society for Rheumatology Biologics Register showed that patients who continued or switched their TNFi post-index SI had a lower risk of recurrent SI infection compared with those who stopped the drug. Reasons for this are discussed, and the clinical implications of the findings are highlighted.